Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/575—Hormones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

• the present invention relates to an active polypeptide compound for the treatment of diabetes mellitus, and particularly to a derivative of the insulinotropic peptide Exendin-4.
• GIP gastric inhibitory peptide
• GLP-1 glucagon-like peptide
• GLP-1 is characterized by its ability to promote islet ⁇ -cells to synthesize proinsulin RNA and proinsulin, which in turn promotes insulin release.
• the effect of GLP-1 on pancreatic ⁇ -cells depends on glucose concentration. When the blood glucose concentration is higher than 6mmol L, it can significantly promote insulin secretion; once the blood glucose concentration returns to normal, it will no longer continue to act, which is important for type II diabetes. The treatment is very useful. Clinical trials in recent years have also shown that GLP-1 can promote insulin secretion and reduce blood glucose levels in patients with type II diabetes.
• World patent application WO 91/11457 discloses glucagon-like polypeptides GLP-1 (7-34), (7-35), (7-36), and (7-37) for treating type II diabetes ).
• Exendin-4 has 53% homology with GLP-1 in the amino acid sequence, and can bind to the GLP-1 receptor. It also promotes insulin secretion, so it is also an insulin-promoting peptide.
• U.S. Patent No. 05424286 discloses a comparison experiment between Exendin-4 and GLP-1 in promoting insulin secretion. Experiments have shown that its ability to promote insulin secretion is stronger than GLP-1, and the concentration required to produce insulin secretion is lower than GLP-1. The half-life in vivo is longer than GLP-1. Based on these characteristics, Exendin-4 may become an ideal medicine for treating type 2 diabetes.
• Exendin-4 can be prepared by chemical synthesis methods, such as peptide synthesizers, but using this method, the cost of the product is high, resulting in a high price, which cannot make it a commercial drug. Therefore, people have tried to use genetic engineering methods. To large-scale low-cost production to achieve commercialization purposes. Object of the invention
• the purpose of the present invention is to provide a class of derivatives of the polypeptide compound Exendin-4, which have the effect of promoting insulin secretion and thereby lowering blood sugar, and thus can be used for treating type II diabetes. They can be prepared not only by chemical synthesis methods, but also easily by recombinant DNA methods, thereby reducing production costs. This provides a summary of possible inventions
• the present invention relates to a class of insulinotropic peptide derivatives of the following structure and salts suitable for use in medicine,
• the amino acid sequence of the insulin-promoting peptide derivative of the present invention is as described in ⁇ 210> 1- ⁇ 210> 4 in the sequence listing.
• the insulin-promoting peptide derivative provided by the present invention is an amphoteric compound and can react with acidic or basic substances to form a salt.
• the acids commonly used to form acid addition salts are: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, Citric acid, benzoic acid, acetic acid, etc.
• salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, hydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate, hydrochloride, Bromide, iodide, acetate, propionate, caprate, caprylate, acrylate, formate, isobutyrate, hexanoate, heptanoate, propionate, oxalate , Malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-diacid, hexyne-1,6-di Acid salt, benzoate salt, chlorobenzoate salt, methylbenzoate salt, dinitrobenzoate salt, hydroxybenzoate salt, methoxybenzoate salt, phenylacetate salt, phenylpropionate Acid salt, phenylbutyrate, citrate, lactate, Y-
• Basic substances can also react with insulin-promoting peptide derivatives to form salts.
• These basic substances include ammonium, alkali metal or alkaline earth metal hydroxides, as well as carbonates, bicarbonates, and the like.
• the preparation method of the insulin-promoting peptide derivative according to the present invention is a solid-phase chemical synthesis method, and the steps include: using a HMP resin as a solid-phase carrier, and using a 9-fluorenylmethoxycarbonyl group for an ⁇ -amino group of an amino acid; The (Fmoc) group is protected, and the peptide synthesizer is used to synthesize the amino acid sequence of the insulin-promoting peptide derivative, and then separated and purified, and lyophilized to obtain the product.
• the method for preparing the insulin-promoting peptide derivative according to the present invention is a genetic engineering method, and the steps include:
• the present invention also provides the application of the insulin secretin-promoting peptide derivative and a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating II diabetes.
• the present invention provides a new class of derivatives of the exendin-4 polypeptide compound, which expands the types of the exendin-4 derivatives of the polypeptide compound. They have biological activities that promote insulin secretion and hypoglycemic effects, and can be used to treat ⁇ diabetes. They can be prepared not only by chemical synthesis methods, but also easily by recombinant DNA methods, thus providing the possibility to reduce production costs.
• the medicinal effect experiment proves that the non-obese diabetic mice (NOD mice) intraperitoneally injected with 0.1 insulin secretin-derived peptide derivative of the present invention can obviously promote insulin secretion and lower blood sugar.
• FIG. 1 is an experimental diagram of the medicinal effect of the insulin-promoting peptide derivative of the invention.
• FIG. 2 is a mass spectrum of the product obtained in Example 1.
• the theoretical molecular weight of the derivative is 4300.6, and the measured value is 4316.7.
• Figure 3 is Exendin 4 (Lys 20 , Arg 40 ) and Exendin 4 (Leu 14 , Lys 20 , Arg 40 ) in the present invention Schematic of the experimental results of hypoglycemic effect.
• FIG. 4 is a schematic diagram of the experimental results of insulin secretion of E Xen din 4 (Lys 20 , Arg 40 ) in the present invention.
• FIG. 5 is a schematic diagram of the experimental results of C-peptide secretion of Exendin 4 (Lys 20 , Arg 40 ) in the present invention. Summary of the invention
• Example 1 A frog skin antibacterial insulin secretion peptide derivative of the structure of the present invention was prepared by a solid-phase chemical synthesis method, where X is Arg, Y is Lys, and Z is -OH.
• Trt trityl
• the reagents are: N-methylpyrrolidone, dichloromethane, hexahydropyridine, methanol, dimethylaminopyridine (I DMF) ⁇ , N-diisopropylethylamine ( ⁇ , ⁇ - diisopropylethylamine) / NMP, HBTU 100 mmole / 0.5 M HOBT in DMF, N, N- Dicyclohexylcarbodiimide / NMP
• DMF is ⁇ , ⁇ -Dimet ylformamide
• NMP is N-methylpyrrolidone
• HOBT 1-Hydroxybenzotriazole
• HBTU 2- (1Hydroxybenzotriazole) -tetramethylurea hexafluorophosphate (2- (1 (-benzotriazole-yl- 1,1 , 3, 3 -tetramethyl-Uronium hexafluorophosphate)
• the 0.25mmol scale Take the 0.25mmol scale as an example, weigh 0.25g of HMP resin, place it in the reactor on the peptide synthesizer, weigh various protective amino acids into 1mmol bottles, and follow the amino acid sequence of the insulinotropic peptide derivative from The C-terminal to N-terminals are arranged in a synthesizer, and at room temperature of 25 ° C, the Fmoc protection, activation, and connection are automatically controlled by a computer program, and then the next cycle is performed to complete the synthesis. After the synthesis is completed, the obtained peptide resin with a side chain protecting group may be dried on a peptide synthesizer and then weighed.
• the protected insulin-promoting peptide derivative polypeptide resin was placed in a conical Erlenmeyer flask, and the lysis reagent was added as shown in the following table:
• the reaction was electromagnetically stirred for 6 hours.
• the filtrate was collected, and the resin was washed with a small amount of trifluoroacetic acid.
• the collection solution and the washing solution were combined, and ether was added to generate a precipitate.
• the precipitate was filtered and washed with a small amount of ether. Dry in a desiccator to obtain a crude product.
• the insulin-promoting peptide derivative of the present invention was prepared by genetic engineering, where X is Leu, Y is Lys, and Z is Arg- OH.
• Plasmid In another test tube, the plasmid containing the lactose promoter Lac (or the temperature-controlled promoter P ⁇ , the tryptophan-lactose mixed promoter Tac) was digested with the restriction enzymes EcoR 1 and Hindlll, and then used. Phenol / chloroform extraction, centrifugation to take the water layer part, and then washing the water layer 3 times with chloroform, centrifugation, precipitation of the water layer with isopropanol, centrifugation, and drying.
• Recipient bacteria culture The clone E. coli (M. coli) JM103 is cultured in a culture solution (LB culture solution) containing 10 g of peptone, 5 g of yeast extract, and 5 g of sodium chloride per liter at 37 ° C with shaking for 4 hours. The bacteria were collected by centrifugation, and after being treated with CaCl 2 solution, they were stored for 4 days.
• a culture solution LB culture solution
• the cloned plasmid was transformed into the recipient bacterium Escherichia coli JM103 cells, maintained in an ice bath for 30 minutes, warmed to 42 ° C, and maintained for 2 minutes, transferred to an agarose plate containing ampicillin, and incubated at 37 ° C overnight. Colony screening yielded clone-positive plasmids.
• culture in a 300ml X 10 shaker induce, and collect the bacterial cells with lysate (1% NaCl, phosphate buffer pH 7.5, 20mM) and lysozyme, incubate at 30 ° C for 30 minutes, collect the pellet by centrifugation, add
• the inclusion bodies were extracted with 6M guanidine hydrochloride (Gu ⁇ ⁇ (31), centrifuged, and the supernatant was dialyzed to remove Gu-HCl, and then a phosphate buffer composed of 1% NaCl and 0.1% Tween 80 ( 20 mM, pH 7.5) Wash the pellet three times to obtain inclusion bodies.
• the inclusion bodies were dissolved in 8M urea solution, hydrochloric acid was added to 50 mM, cyanogen bromide was added, protected from light, stirred under nitrogen protection, and lysed for 2 hours, followed by HPLC analysis.
• mice non-obese diabetic mice (NOD mice), weighing 17g ⁇ 2g, fasting for 2 hours
• Control group 1 Intraperitoneal injection of insulin 2 g
• Control group 2 Intraperitoneal injection of insulin 4 ⁇ g
• Example 4 Hypoglycemic effect of Exendin 4 (Lys 20s Arg 40 ) and Exendin 4 (Leu 14 , Lys 20 , Arg 40 ) on NOD mice
• NOD mice were fasted overnight (provided by Shanghai Animal Center, Chinese Academy of Sciences)
• Exendin 4 (Lys 20 , Arg 40 ), Exendin 4 (Leu 14 , Lys 20 , Arg 40 ) blood glucose measurement kit (produced by Shanghai Biological Products Ministry of Health)
• NOD mice were fasted overnight and divided into three groups.
• the first group was injected intraperitoneally with 200 ⁇ l of 40% glucose and 1 ⁇ g Exendin 4 (Lys 20 , Arg 40 ), and the second group was injected intraperitoneally with 200 ⁇ l of 40% glucose and 2 ⁇ g Exendin 4 (Leu 14 , Lys 20 , Arg 40 )
• the third group was the control group and only injected glucose.
• a graduated capillary tube treated with heparin before injection
• the blood glucose concentration of the three groups of serum was measured according to the method described in the kit to test the hypoglycemic effect of GLP-1 (7-36).
• Radioimmunoassay kit (produced by Shanghai Biological Products Ministry of Health)
• NOD mice were divided into two groups. First, 50 microliters of blood was collected from the fundus vein plexus with graduated capillary (the inner wall of the capillary was rinsed with 1 mg / mL heparin and dried), and then two groups of mice were injected intraperitoneally with 5 micrograms of Exendin 4 (Lys 2 , Arg 4Q ) and 200 microliters of physiological saline was recorded, and the time was zero. Then take blood at 5, 10, 20 and 30 minutes. Immediately after the blood was taken, each blood sample was added to a centrifuge tube containing 50 microliters of physiological saline, mixed, and the red blood cells were removed at 3,000 rpm to separate the hearts. The insulin concentration in the serum was measured according to the method of the radioimmunity kit to test Exendin 4 (Lys 20 , Arg 4Q ).
• Radioimmunoassay kit (produced by Shanghai Biological Products, Ministry of Health, China)
• Radioimmunoassay C-peptide assay kit produced by Shanghai Biological Products, Ministry of Health
• Healthy C 57 / BL mice were divided into two groups. Firstly, 50 microliters of blood was taken from the fundus venous plexus with graduated capillaries (the inner wall of the capillary was rinsed with 1 mg / mL heparin and dried), and then two groups of mice were injected intraperitoneally with 5 micrograms of Exendin 4 (Lys 20 , Arg 4Q ) and 200 Slightly increase the physiological saline and record it as the zero moment. Then take blood at 5, 10, 20 and 30 minutes. Immediately after the blood was taken, each blood sample was added to a centrifuge tube containing 50 microliters of normal saline, mixed, and the blood cells were removed at 3000 rpm to separate the red blood cells. The concentration of C peptide in the serum was measured according to the method of using the radioimmunity kit to test Exendin 4 (Lys 20 , Arg 40 ) promotes C-peptide secretion.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Biophysics (AREA)
• Toxicology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Diabetes (AREA)
• Biochemistry (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Endocrinology (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Obesity (AREA)
• Emergency Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Hematology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=4659603

Family Applications (1)

Country Status (9)

Cited By (2)

Families Citing this family (33)

Citations (4)

Family Cites Families (10)

• 2001
  • 2001-05-10 CN CNB011128569A patent/CN1162446C/zh not_active Expired - Lifetime
• 2002
  • 2002-05-08 EP EP10001237.6A patent/EP2223938B1/en not_active Expired - Lifetime
  • 2002-05-08 WO PCT/CN2002/000316 patent/WO2002090388A1/zh not_active Ceased
  • 2002-05-08 EP EP02727167A patent/EP1386930A4/en not_active Withdrawn
  • 2002-05-08 JP JP2002587464A patent/JP4287153B2/ja not_active Expired - Lifetime
  • 2002-05-08 CA CA2446394A patent/CA2446394C/en not_active Expired - Lifetime
  • 2002-05-08 KR KR1020037014451A patent/KR100902208B1/ko not_active Expired - Lifetime
  • 2002-05-08 AU AU2002257497A patent/AU2002257497B2/en not_active Expired
  • 2002-05-08 BR BRPI0209685A patent/BRPI0209685B8/pt not_active IP Right Cessation
• 2003
  • 2003-11-07 US US10/704,409 patent/US7329646B2/en not_active Expired - Lifetime

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events